Publications by authors named "Elliot Norry"

Claim this Profile
P
Phase I trial of ADP-A2AFP TCR T-cell therapy in patients with advanced hepatocellular or gastric hepatoid carcinoma.
Tim Meyer, Richard S Finn, Mitesh Borad, Amit Mahipal, Julien Edeline, Elliot Norry

J Hepatol· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial.
Sandra P D'Angelo, Dejka M Araujo, Albiruni R Abdul Razak, Mark Agulnik, Steven Attia, Elliot Norry

Lancet· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Durable control of metastases in an HLA-A2+ patient with refractory melanoma after low-dose radiotherapy in combination with MAGE-A4 T cell therapy: a case report.
Kewen He, David S Hong, Danxia Ke, Partow Kebriaei, Tianjiao Wang, Elliot Norry

Melanoma Res· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Autologous T cell therapy for MAGE-A4 solid cancers in HLA-A*02 patients: a phase 1 trial.
David S Hong, Brian A Van Tine, Swethajit Biswas, Cheryl McAlpine, Melissa L Johnson, Elliot Norry

Nat Med· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 Clinical Trial Evaluating the Safety and Anti-Tumor Activity of ADP-A2M10 SPEAR T-Cells in Patients With MAGE-A10+ Head and Neck, Melanoma, or Urothelial Tumors.
David S Hong, Marcus O Butler, Russell K Pachynski, Ryan Sullivan, Partow Kebriaei, Elliot Norry

Front Oncol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10 advanced non-small cell lung cancer.
George R Blumenschein, Siddhartha Devarakonda, Melissa Johnson, Victor Moreno, Justin Gainor, Elliot Norry

J Immunother Cancer· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Newly developed pseudogout arthritis after therapy with MAGE-A4 directed TCR T cells responded to treatment with tocilizumab.
Sang T Kim, Jean Tayar, Siqing Fu, Danxia Ke, Elliot Norry

J Immunother Cancer· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term safety and activity of NY-ESO-1 SPEAR T cells after autologous stem cell transplant for myeloma.
Edward A Stadtmauer, Thomas H Faitg, Daniel E Lowther, Ashraf Z Badros, Karen Chagin, Elliot Norry

Blood Adv· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tuning T-Cell Receptor Affinity to Optimize Clinical Risk-Benefit When Targeting Alpha-Fetoprotein-Positive Liver Cancer.
Roslin Y Docta, Tiago Ferronha, Joseph P Sanderson, Thomas Weissensteiner, George R Pope, Elliot Norry

Hepatology· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fludarabine and neurotoxicity in engineered T-cell therapy.
Kate L Lowe, Crystal L Mackall, Elliot Norry, Rafael Amado, Bent K Jakobsen

Gene Ther· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterisation of liver chemistry abnormalities associated with pazopanib monotherapy: a systematic review and meta-analysis of clinical trials in advanced cancer patients.
Thomas Powles, Sergio Bracarda, Mei Chen, Elliot Norry, Natalie Compton

Eur J Cancer· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis